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Although the importance of the progesterone receptor (PR) to female reproductive and mammary gland biology
is firmly established, the coregulators selectively co-opted by PR in these systems have not been clearly
delineated. A selective gene-knockout approach applied to the mouse, which abrogates gene function only
in cell types that express PR, recently disclosed steroid receptor coactivator 2 (SRC-2, also known as TIF-2
or GRIP-1) to be an indispensable coregulator for uterine and mammary gland responses that require
progesterone. Uterine cells positive for PR (but devoid of SRC-2) were found to be incapable of facilitating
embryo implantation, a necessary first step toward the establishment of the materno-fetal interface. Importantly,
such an implantation defect is not exhibited by knockouts for SRC-1 or SRC-3, underscoring the unique
coregulator importance of SRC-2 in peri-implantation biology. Moreover, despite normal levels of PR, SRC-1
and SRC-3, progesterone-dependent branching morphogenesis and alveologenesis fails to occur in the murine
mammary gland in the absence of SRC-2, thereby establishing a critical coregulator role for SRC-2 in signaling
cascades that mediate progesterone-induced mammary epithelial proliferation. Finally, the recent detection
of SRC-2 in the human endometrium and breast suggests that this coregulator may represent a new clinical
target for the future management of female reproductive health and/or breast cancer.
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Family ties: SRC-2 is a member of the
steroid receptor coactivator/p160 family
Pioneering in vitro studies by the O’Malley group revealed
that the transactivational potency of agonist bound
progesterone receptor (PR) can be significantly enhanced
by increasing the cellular level of members of the steroid
receptor coactivator (SRC/p160) family of coregulators,
reviewed in [McKenna and O'Malley, 2002].The
SRC/p160 family consists of three members: SRC-1
(ERAP140/ERAP160/NcoA-1); SRC-2
(TIF-2/GRIP-1/NcoA-2); and SRC-3
(p/CIP/RAC3/AIB1/TRAM-1/ACTR/NcoA-3); reviewed in
[Lonard and O'Malley, 2005].To enhance nuclear receptor
(NR)-mediated transactivation, each SRC family member
has been shown to directly contact - through discreet
LXXLL motifs within their NR interaction domain (Figure
1) - the highly conserved activation 2 domain located in
the C-terminal region of NRs. Furthermore, two activation
domains (AD1 and AD2) positioned in the C-terminal
region of each SRC are responsible for recruiting
secondary coregulators (or co-coregulators). For example,
AD1 is known to interact with histone acetyltransferases
(HATs) p300 and the related cyclic AMP-response
element binding protein (CREB)-binding protein (CBP),
whereas AD2 is known to recruit arginine
methyltransferases such as coactivator-associated
arginine methyltransferase 1 (CARM1), reviewed in
[Lonard and O'Malley, 2006].The histone-modifying
activities of these secondary coregulators (in addition to
the weak intrinsic HAT activity of SRC members) facilitate
local chromatin remodeling that allows the general
transcriptional machinery open access to promoter
regions of NR target genes. Apart from histones, these
co-coregulators have been shown to posttranslationally
modify other target proteins (i.e., other coregulators and
transcription factors) within the transcriptional complex.
The N-terminally positioned basic helix loop
helix-Per/ARNT/Sim (bHLH-PAS) domain is the most
conserved structural motif among SRC members (Figure
1) and is also responsible for co-opting additional
coregulators and transcription factors. For SRC-2, these
coregulators include coiled-coil coactivator (CoCoA) [Kim
et al., 2003], flightless-I (Fli-I) [Lee and Stallcup, 2006],
GRIP1-associated coactivator 63 (GAC63) [Chen et al.,
2005], as well as the transcription factors
myocyte-enhancer factor 2C (MEF-2C) [Chen et al.,
2000b] and TEF4 [Belandia and Parker, 2000]. In the
case of other regulatory proteins, the bHLH-PAS motif
has been shown to be involved in both DNA and ligand
binding [Gu et al., 2000; Huang et al., 1993], indicating
that this structural domain feature may be involved in
SRC regulatory functions beyond those currently known.
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the domain structure of human (h) SRC-1, -2, and -3 proteins.The basic
helix loop helix, Per/ARNT/Sim, receptor interaction and activation
domains are indicated by bHLH, PAS, RID, and AD, respectively.The
amino acid region associated with histone acetyl transferase (HAT) activity
in SRC-1 and -3 is also denoted; Q indicates the glutamine-rich region.
Also shown is the similarity and (identity) of amino acid sequences within
key functional domains of SRC members. Overall amino acid similarity
and (identity) between SRC members is: hSRC1/2, 54% (46%); hSRC1/3,
50% (43%); and hSRC2/3, 55% (48%). Amino acid sequence alignments
were conducted using LALNVIEW software (Duret et al., 1996). Panel B
shows an schematic model in which the pairing of SRC-2 with PR at the
genome comprises part of a dynamic multiprotein transcriptional complex
in which such co-coregulators as p300 (Chen et al., 2000a), CARM-1
(Chen et al., 1999), FLASH (Kino et al., 2004), GAC63 (Chen et al., 2005),
and CoCoA (Kim and Stallcup, 2004) differentially assemble and
disassemble depending on a particular input signal, such as a distinct
phosphorylation event mediated by a growth factor or cell survival
signal-induced kinase.
Superimposed on the myriad of protein-protein
interactions that enable SRC-2 to relay (and control)
signaling inputs dispatched from ligand-bound NR to the
general transcriptional complex, a multiplicity of interacting
signaling inputs (i.e., phosphorylation events triggered
by extracellular growth and cell survival factors [Duong
et al., 2006; Frigo et al., 2006]) are also being transduced
by SRC-2 within the multicomponent transcriptional
machinery. Although SRC-2 has been primarily
considered a coactivator, a subset of investigations
provide strong support for a corepressor role for SRC-2
within certain cellular contexts [Gupta et al., 2007; He
and Simons, 2007; Rogatsky et al., 2002;Wang et al.,
2007]; these studies highlight the versatility and
complexity of this multifunctional coregulator.
While in vitro experiments disclosed the existence of the
SRC family, subsequent experimental mouse genetics
would uncover important overlapping and non-overlapping
roles for the three SRCs in progestin-initiated signaling
events in vivo. Further underscoring their multifunctional
properties, mouse studies have also uncovered critical
roles for each SRC in signaling processes that reside
outside the physiologic area of progestin control.
A subgroup of progestin-dependent
physiological processes require SRC
members: insights from mouse studies
The SRC-1 knockout (KO) mouse was shown to display
an attenuated decidual response in the uterus [Xu et al.,
1998], suggesting that this coregulator (in concert with
others) is required for complete manifestation of this
morphological response, which requires initial
progesterone stimulation. Although the SRC-3KO exhibits
a normal decidual response, a partial block in
hormone-induced mammary ductal side-branching and
alveologenesis is observed in this animal [Xu et al., 2000].
Collectively, these observations support the proposal that
SRC-1 and -3 are required for a subgroup of PR-mediated
transcriptional responses in the uterus and mammary
gland, respectively. Investigations on the PR activity
indicator (PRAI) model provide further support for this
supposition [Han et al., 2006; Han et al., 2005]. Mouse
studies have also underscored important roles for SRC-1
and SRC-3 in areas of normal physiology and disease
which are outside the realm of progesterone control, these
include: cell growth [Wang et al., 2000; Xu et al., 2000],
metabolism [Louet et al., 2006;Wang et al., 2006], thyroid
hormone-based physiology [Ying et al., 2005], bone
homeostasis [Modder et al., 2004], prostate biology [Zhou
et al., 2005] and B-cell lymphoma developmental
progression [Coste et al., 2006].
In contrast to KOs for SRC-1 and -3, the global KO for
SRC-2 (termed:Transcriptional Intermediary Factor 2 KO
(or TIF2
-/-)) displays striking reproductive abnormalities
in both sexes [Gehin et al., 2002]. In the female,
abrogation of SRC-2 function triggers placental
hypoplasia, which results in a severe hypofertility defect.
Subsequent studies found that TIF2
-/- pups (both sexes)
are significantly underrepresented in litters from TIF2
+/-
crosses (TIF2
-/- females resulting from such crosses are
infertile (personal observations)). Similar to KOs for
SRC-1 and -3, global ablation of SRC-2 function results
in physiological defects not directly linked to reproductive
biology, such as a decrease in early postnatal survival
[Mark et al., 2004], a breakdown in energy homeostasis
[Jeong et al., 2006], as well as elaboration of insidious
adrenocortical insufficiency [Patchev et al., 2007]).
Cell lineage-specific abrogation of
SRC-2 function in the mouse reveals a
critical coregulator role for SRC-2 in a
subset of physiological processes that
require progesterone action
The placental defect exhibited by the global KO for
SRC-2, in conjunction with the recent observation that a
subset of murine cell lineages express both PR and
SRC-2 [Mukherjee et al., 2006b], suggested that SRC-2
(like SRC-1 and -3) may occupy a critical coregulator role
in a subgroup of physiological processes that require PR
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Cre/+SRC-2
flox/flox
bigenic mouse was created [Mukherjee et al., 2006b] by
crossing a PR
Cre/+ knockin mouse [Soyal et al., 2005] with
a SRC-2
flox/flox mouse in which exon 11 of the SRC-2 gene
was floxed to enable cre-mediated excision [Gehin et al.,
2002]; exon 11 encodes the receptor-interacting domain
(RID).Therefore, the PR
Cre/+SRC-2
flox/flox bigenic is
designed to abrogate SRC-2 function specifically in cell
lineages that are PR positive [Mukherjee et al., 2006b].
The utility of this genetic strategy is that SRC-2’s role in
PR-regulated transcriptional programs can be directly
investigated at the whole-animal level without interference
from other, unrelated phenotypes resulting from SRC-2’s
absence (a key advantage over the global KO for SRC-2).
SRC-2 is required for uterine receptivity
To date, female and male PR
Cre/+SRC-2
flox/flox mice show
normal postnatal development; however, the
PR
Cre/+SRC-2
flox/flox female is sterile [Mukherjee et al.,
2006b]. Unlike the TIF2
-/- mouse, male PR
Cre/+SRC-2
flox/flox
mice exhibit normal fertility and neither sex displays
phenotypes (outside progestin control) previously
described for the TIF2
-/- model [Gehin et al., 2002].
The absence of implantation sites along the uterine horn
of the PR
Cre/+SRC-2
flox/flox mouse (5.5 days post-coitum)
is the primary underlying cause for the infertility defect
displayed by the PR
Cre/+SRC-2
flox/flox female (Figure 2A).
This result suggests a pivotal role played by SRC-2 in
the early cellular changes in the uterus that are required
for embryo implantation. Although the SRC-2
flox/flox uterus
(a positive control) exhibits a full decidual response to an
artificial deciduogenic stimulus (Figure 2B and C), the
PR
Cre/+SRC-2
flox/flox uterus displays only a partial decidual
response (Figure 2B and C).These findings support the
proposal that a subgroup of PR-mediated transcriptional
events are dependent on SRC-2 to launch a complete
decidual reaction.The incomplete decidual response
phenotype shared by the SRC-1KO [Xu et al., 1998] and
PR
Cre/+SRC-2
flox/flox mouse suggests that both SRC
coregulators may be required together in PR-mediated
signaling cascades that result in a fully decidualized
uterus.To test this hypothesis, the SRC-1KO mutation
was introduced into the PR
Cre/+SRC-2
flox/flox germline to
generate a PR
Cre/+SRC-2
flox/flox SRC-1KO trigenic model.
Figure 2B and C shows that the trigenic uterus fails to
mount a decidual response, thereby furnishing essential
in vivo support for a cooperative involvement for SRC-1
and SRC-2 in the progesterone-dependent decidual
reaction. Note that the PR
Cre/+SRC-2
flox/flox uterine
phenotype is not explained by changes in the normal
levels of uterine SRC-1 and/or SRC-3 protein (Figure
2D).
In contrast to the uterus, ovarian and pituitary function is
not compromised in the PR
Cre/+SRC-2
flox/flox mouse,
suggesting that PR enlists other coregulators in these
systems (normal ovarian and pituitary functionality is
severely diminished in the PRKO [Lydon et al., 1995]).
Furthermore, SRC-2 is not required for
progesterone-inhibition of PR expression or suppression
of estrogen-induced luminal epithelial proliferation in the
uterus. Collectively, these observations suggest that the
selective enlistment of SRC-2 by PR in female
reproductive tissues may provide one explanation as to
why different reproductive tissues display different
responses to the same progesterone signal.
Figure 2.  Abrogation of uterine SRC-2 results in a block in embryo
implantation and a partial decidual response. In panel A, arrows
show the location of implantation sites in the uterus (1) of a SRC-2
flox/flox
(or wild-type (WT)) mouse (5.5 days post coitum (d.p.c.)). However,
implantation sites were not detected in uteri from similarly treated
PR
Cre/+SRC-2
flox/flox (2) mice.The average number of implantation sites
per genotype per total number of mice examined is tabulated. In panel
B, the gross morphological response of the left (L) uterine horn to a
deciduogenic stimulus for SRC-2
flox/flox (1), PR
Cre/+SRC-2
flox/flox (2), and
PR
Cre/+SRC-2
flox/flox SRC-1KO trigenic (3) mice is shown.The right (R)
uterine horn represents the unstimulated control. Although the
PR
Cre/+SRC-2
flox/flox uterus (2) exhibits a limited decidual response, note
the absence of a decidual response in the PR
Cre/+SRC-2
flox/flox SRC-1KO
trigenic uterus (3). Panel C graphically presents the average weight ratios
(± standard deviation (SD)) of stimulated (L) to control (R) horn for
SRC-2
flox/flox (1), PR
Cre/+SRC-2
flox/flox (2), and PR
Cre/+SRC-2
flox/flox SRC-1KO
trigenic (3) uteri.Western analysis in panel D reveals uterine tissue from
untreated adult virgin SRC-2
flox/flox (1) and PR
Cre/+SRC-2
flox/flox (2) mice show
equivalent levels of uterine SRC-1 and SRC-3 (loading control is β-actin).
Modified from (Mukherjee et al., 2006b) (Copyright (2006) American
Society for Microbiology).
Having disclosed a central role for uterine SRC-2 in
murine peri-implantation biology, future questions to be
addressed include: (1) Is uterine SRC-2 expression in
the epithelial, stromal, or both cellular compartments
required for the development of the receptive uterus? (2)
Is SRC-2 expressed in the embryonic-derived
trophectoderm? If so, is trophectoderm-derived SRC-2
required for embryo implantation? (3) Does uterine SRC-2
possess coregulator functions necessary for later stages
of pregnancy? For example, in the regulation of the onset
of parturition; and (4) Does SRC-2 have a role in the
etiopathogenesis of such endometrial disorders as uterine
hyperplasia and/or endometriosis?
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Review SRC-2 in female reproductive and mammary gland biologyFigure 3.  Absence of mammary SRC-2 function blocks progestin-induced ductal side-branching and alveologenesis. Panels A and B show
whole-mounts of mammary glands from SRC-2
flox/flox and PR
Cre/+SRC-2
flox/flox mice (following three weeks of estrogen plus progesterone (EP) exposure),
respectively. Unlike the SRC-2
flox/flox mammary gland (positive control), note the marked reduction in branching morphogenesis (black arrow) in the
PR
Cre/+SRC-2
flox/flox gland. Panels C and D represent hematoxylin and eosin (H&E) stained sections of tissue shown in panels A and B, respectively.
Compared to the SRC-2
flox/flox gland (panel C), note the conspicuous reduction in the epithelial compartment in the PR
Cre/+SRC-2
flox/flox gland (panel D
(arrowhead)).The graph in panel E displays the average percentage of mammary epithelial cells (± standard deviation (S.D.)) positive for BrdU
incorporation in the hormone-treated SRC-2
flox/flox and PR
Cre/+SRC-2
flox/flox glands. Inset shows an SRC-2
flox/flox (1) and PR
Cre/+SRC-2
flox/flox (2) immunoblot
for mammary SRC-1 and -3. In comparison to SRC-2
flox/flox, changes in SRC-1 and -3 protein levels are not observed in the PR
Cre/+SRC-2
flox/flox mammary
gland (β-actin acts as a loading control). Scale bars in panels A and C apply to B and D, respectively. Modified from (Mukherjee et al., 2006b) (Copyright
(2006) American Society for Microbiology).
Postnatal mammary morphogenesis
requires SRC-2 function
The detection of SRC-2 protein in mammary epithelial
cells that are PR positive [Mukherjee et al., 2006b]
suggested that mammary SRC-2 may occupy a crucial
role in PR-mediated proliferative programs which result
in ductal side-branching and alveolar morphogenesis in
the mammary gland of the adult.This assumption was
supported by the observation that the PR
Cre/+SRC-2
flox/flox
mammary gland fails to exhibit the typical morphological
changes that occur with combined estrogen and progestin
exposure (Figure 3A-D). Like the PRKO [Lydon et al.,
1999], the underlying cause of the PR
Cre/+SRC-2
flox/flox
mammary phenotype is a failure of the mammary
epithelium to proliferate in response to hormone (Figure
3E).These results support an essential role for SRC-2
in progesterone-induced signaling programs which are
required for mammary morphogenesis in the adult. Of
note, the PR
Cre/+SRC-2
flox/flox mammary defect was not
compensated for by SRC-3 (Figure 3E). Although SRC-3
has been shown to be involved in steroid-induced
mammary morphogenesis [Xu et al., 2000], as well as
tumorigenesis [Kuang et al., 2005; Kuang et al., 2004;
Torres-Arzayus et al., 2004], our data to date suggest
that SRC-2 and -3 are operationally distinct in the murine
mammary epithelial cell. Irrespective of the functional
interrelationships between SRC-2 and other members of
the SRC family in this tissue, our studies reveal SRC-2
to be an important coactivator for progestin-initiated
signaling in the mammary epithelium. An important
question for the future will be to determine whether SRC-2
(like SRC-3/AIB-1 [Anzick et al., 1997]) can act as a
mammary oncogene.
Relevance to the human…
Although state-of-the-art genetics demonstrated a critical
role for SRC-2 in a subset of progesterone responses in
the uterus and mammary gland of the mouse, whether
these findings translate to the human is now an important
research focus. As previously shown [Hofman et al.,
2002], the transactivational potency of the human PR
ortholog is significantly enhanced with increasing levels
of human SRC-2 (Figure 4A).These observations provide
strong support for a coregulator involvement for SRC-2
in progestin-dependent physiological processes in the
human. As further support for this supposition,
immunohistochemistry demonstrates that SRC-2 protein
is expressed in a subset of steroid-responsive target
tissues in the human (Figure 4B-F). In the case of human
prostate, (Figure 4B), SRC-2 expression is regionally
restricted to the epithelial compartment, a known cellular
target-site for androgen receptor-mediated signaling and
neoplastic transformation [Berrevoets et al., 2004; Culig
et al., 2002;Ye et al., 2005]. In the human endometrium,
immunohistochemical studies clearly demonstrate that
SRC-2 and PR are expressed in identical cell types within
the stromal and epithelial compartments (Figure 4C-D);
similar findings have been described for the mouse
[Mukherjee et al., 2006b].
Similar to the murine mammary gland [Mukherjee et al.,
2006b], immunohistochemical investigations have shown
that a subgroup of epithelial cells within the normal human
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Review SRC-2 in female reproductive and mammary gland biologyFigure 4.  Steroid hormone responsive tissues express SRC-2 in the human. Panel A shows the increase in ligand-dependent transactivational
potency of human PR-B is dependent on increased levels of human SRC-2 (red bars ± S.D.); in the absence of ligand, this increase is not observed
(blue bars). For these experiments, human PR-B; SRC-2 (both cloned into pCR3.1) and the luciferase reporter pGRE.E1b.LUC were transiently
cotransfected into HeLa cells in the presence or absence of 10
-7M R5020, as described previously (Lonard et al., 2004); results are expressed in relative
light units (RLU). Panel B shows SRC-2 is expressed in the majority of epithelial cells of the human prostate (black arrow), an established cellular target
for androgen receptor action (Culig et al., 2002); note: the stromal compartment registers negative for SRC-2 expression (blue arrow). Panels C and
D show transverse sections of the luminal and stromal compartment (with surrounding stroma) of the human endometrium stained for PR and SRC-2
expression, respectively. Note that PR and SRC-2 are detected in nuclei of the same cell types in both cellular compartments (black and red arrows,
respectively).The blue arrow in panels C and D highlights a stromal cell negative for PR and SRC-2 expression, respectively; scale bar in panel C
applies to panel D. Endometrial biopsies were obtained by endometrial pipelle from healthy women with normal cycles (aged between 18-35 years)
during the mid-secretory (luteal) phase of the menstrual cycle (days 20-24, which is based on the ideal 28 day cycle, in which day 1 represents the first
day of menstrual flow and day 14 the day of ovulation); cycle phase was determined relative to the timing of the urinary luteinizing hormone (LH) surge.
Immunohistochemical detection of human SRC-2 and PR was undertaken using established methods previously reported by our group (Lee et al.,
2005; Mukherjee et al., 2006b). Panel E shows a representative example of a normal type 1 terminal ductal lobular unit (TDLU) of the human breast
in which SRC-2 expression is restricted to the epithelial compartment (black arrow). Panel F is a higher magnification of the region indicated by the
black arrow in panel E. Note that SRC-2 expression is confined to a subset of epithelial cells of the TDLU (black arrow indicates an epithelial cell scoring
positive for SRC-2 expression, whereas the red arrow highlights an epithelial cell which is negative for SRC-2 expression; blue arrow denotes a stromal
cell which is negative for SRC-2 expression). Interestingly, the spatial expression pattern of mammary SRC-2 resembles that previously reported for
ER-α and PR in the human breast (Clarke et al., 1997).With institutional review board approval, human tissue samples were obtained from Baylor
College of Medicine affiliated hospitals. Modified from (Mukherjee et al., 2006a) (Copyright (2006) Elsevier, B.V.).
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the punctate spatial expression pattern for SRC-2 in the
human breast parallels a similar spatial expression pattern
reported for PR in the rodent and human breast [Clarke
et al., 1997]. However, whether (like the mouse
[Mukherjee et al., 2006b]) SRC-2 and PR localize to
identical cells in the human breast has yet to be
demonstrated. Further progress in this area is important,
as separation of PR positive mammary epithelial cells
from PR negative cells that undergo cell division in
response to progesterone is now recognized as an
evolutionarily conserved feature that underpins a
proposed paracrine mechanism action for PR in the
normal breast, reviewed in [Fernandez-Valdivia et al.,
2005].
Conclusions and perspective
Despite over 200 known coactivators reported [Lonard
and O'Malley, 2006], it is significant that PR action is
singularly dependent on the coregulator functions of
SRC-2 for a subgroup of progesterone-induced
physiological responses that are necessary for the
maintenance of female fertility and postnatal mammary
morphogenesis in the mouse.
Overtly distinct from SRC-1 and SRC-3, coregulator
properties of which subserve only a selection of
progesterone-initiated transcriptional responses either in
the uterus or mammary gland, SRC-2 exerts potent
coregulator activities in both progesterone target tissues.
From a clinical standpoint, the indispensable role of
SRC-2 in murine peri-implantation biology demands
further study, since recurrent implantation failure is now
recognized as a key underlying factor that precludes the
establishment of a successful pregnancy [Norwitz et al.,
2001]). Importantly, abnormal increases in endometrial
SRC-2 levels have also been associated with infertility in
women with polycystic ovarian syndrome (PCOS) and
with a subset of endometrial cancers [Gregory et al.,
2002; Pathirage et al., 2006]. Although preliminary, these
latter observations suggest a possible connection
between perturbation in SRC-2 protein levels and the
etiopathogenesis of these uterine disorders.
In the case of the murine mammary gland, previous
studies demonstrated that PR action is necessary for
parity-induced mammary proliferation, which represents
a prerequisite developmental step prior to terminal
differentiation of this tissue; importantly, the progesterone
signal can also influence breast cancer susceptibility,
reviewed in [Fernandez-Valdivia et al., 2005].The finding
that SRC-2 ablation results in a mammary phenotype
similar to the PRKO mammary defect has prompted three
key questions: (1) Can upregulation of SRC-2 expression
promote neoplastic transformation in the murine
mammary gland? (2) If so, does SRC-2 have an
involvement in hormone-responsive breast cancers in the
human? and (3) Does the established oncogenic effects
of SRC-3 require the presence of SRC-2?
Obviously, addressing these questions will extend our
current understanding of progesterone’s role in breast
cancer promotion and/or progression, and thus may
enable the formulation of more powerful diagnostic,
prognostic and/or therapeutic approaches in the future
clinical containment of this cancer.
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